BRAF mutation (any)

Any BRAF mutation (V600 and non-V600 classes) detected by sequencing; used as a predictive and, in some settings, prognostic marker.

CI-BIO-00000019BRAF graph →NCIt C40430 Tumor-agnostic · 4 approval rows

Also calledBRAF-mutant · BRAF-mutated · non-V600 BRAF · class II/III BRAF

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Dabrafenib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Dabrafenib US FDA · May 29, 2013 · drug in derived setRegulatory approved
Trametinib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Trametinib US FDA · May 29, 2013 · drug in derived setRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (32)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Melanoma	75	72	2	1	3 / 40 / 14 / 18 / 0
Malignant Colorectal Neoplasm	67	54	13	—	1 / 43 / 10 / 12 / 1
Cutaneous Melanoma	22	22	—	—

Derived

Drugs with predictive evidence (43)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
VemurafenibSmall Molecule	92	72	20	A	55 / 22	Childhood Pilocytic Astrocytoma, Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor +16
TrametinibSmall Molecule	53	51	2	A	50 / 2	Childhood Low Grade Glioma, Childhood Pilocytic Astrocytoma, Cholangiocarcinoma, Cutaneous Melanoma +13
DabrafenibSmall Molecule	40	33	7	A	34 / 11	Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor, Ganglioglioma +9
CetuximabMonoclonal Antibody	24	11	13	A	9 / 10	Malignant Colorectal Neoplasm, Solid Neoplasm
PanitumumabMonoclonal Antibody	14	8	6	B	5 / 4	Cholangiocarcinoma, Malignant Colorectal Neoplasm
IrinotecanSmall Molecule	12	5	7	B	5 / 6	Cholangiocarcinoma, Malignant Colorectal Neoplasm
SorafenibSmall Molecule	10	9	1	C	9 / 1	Childhood Pilocytic Astrocytoma, Cutaneous Melanoma, Malignant Colorectal Neoplasm, Melanoma +1
CobimetinibSmall Molecule	7	7	—	A	8 / 0	Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
EncorafenibSmall Molecule	6	6	—	A	6 / 0	Malignant Colorectal Neoplasm, Melanoma
Mitogen-Activated Protein Kinase Kinase Inhibitor	6	6	—	B	5 / 0	Cutaneous Melanoma, Melanoma
BevacizumabMonoclonal Antibody	5	3	2	B	3 / 2	Malignant Colorectal Neoplasm, Spindle Cell Sarcoma
BRAF Inhibitor	5	5	—	B	4 / 0	Melanoma
SelumetinibSmall Molecule	5	4	1	B	2 / 2	Childhood Pilocytic Astrocytoma, Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
OxaliplatinSmall Molecule	4	—	4	B	0 / 4	Malignant Colorectal Neoplasm
BinimetinibSmall Molecule	3	3	—	A	3 / 0	Malignant Colorectal Neoplasm, Melanoma
TovorafenibSmall Molecule	2	2	—	A	4 / 0	Childhood Low Grade Glioma
CapecitabineSmall Molecule	2	1	1	B	1 / 1	Malignant Colorectal Neoplasm
DactolisibSmall Molecule	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
PLX4720	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
TemsirolimusSmall Molecule	2	2	—	C	2 / 0	Spindle Cell Sarcoma
U0126	2	—	2	D	0 / 2	Cutaneous Melanoma
UprosertibSmall Molecule	2	2	—	D	2 / 0	Melanoma
Regorafenib AnhydrousSmall Molecule	2	1	1	C	0 / 1	Gastrointestinal Stromal Tumor
MEK Inhibitor RO4987655	2	—	2	B	—	Melanoma
AlpelisibSmall Molecule	1	1	—	B	1 / 0	Malignant Colorectal Neoplasm
AtezolizumabMonoclonal Antibody	1	1	—	A	1 / 0	Melanoma
BelvarafenibSmall Molecule	1	1	—	C	1 / 0	Melanoma
Chemotherapy	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
Dabrafenib/Trametinib Regimen	1	1	—	C	1 / 0	Histiocytic Sarcoma
ErlotinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
EverolimusSmall Molecule	1	1	—	D	1 / 0	Childhood Low Grade Glioma
FOLFOX-4 Regimen	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
GDC-0879Small Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
GefitinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
JQEZ5	1	1	—	D	1 / 0	Melanoma
MEK Inhibitor REC-4881	1	1	—	C	1 / 0	Cutaneous Melanoma
Nutlin-3Small Molecule	1	1	—	D	1 / 0	Melanoma
Pan-RAF Inhibitor LY3009120Small Molecule	1	1	—	D	1 / 0	Malignant Neoplasm
PertuzumabMonoclonal Antibody	1	1	—	C	1 / 0	Thyroid Gland Anaplastic Carcinoma
PictilisibSmall Molecule	1	1	—	C	1 / 0	Melanoma
Pictilisib Bismesylate	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
RefametinibSmall Molecule	1	—	1	C	0 / 1	Melanoma
MirdametinibSmall Molecule	1	—	1	D	—	Melanoma

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (214)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–50 of 214 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF V600E + BRAF Fusion1
Tovorafenib	Childhood Low Grade Glioma	Predictive	A	Supports Sensitivity Response	5	accepted	EID12016 In this ongoing phase 2 trial (FIREFLY-1), 76 patients, aged 6 months to 25 years, with pediatric low-grade glioma harbouring BRAF alterations (BRAF fusions or BRAF V600E mutations) were treated with … (full text at CIViC) PMID 37978284 · Kilburn et al., 2024 · Open in CIViC	civic
BRAF V600 + BRAF Fusion1
Tovorafenib	Childhood Low Grade Glioma	Predictive	A	Supports Sensitivity Response	5	accepted	EID12028 In this phase 2 clinical trial, the efficacy of RAF inhibitor tovorafenib (DAY-101) was investigated in patients between the ages of 6 months and 25 years, with pediatric low-grade gliomas harbouring … (full text at CIViC) PMID 37978284 · Kilburn et al., 2024 · Open in CIViC	civic
BRAF Fusion5
Everolimus + TrametinibCombination	Childhood Low Grade Glioma	Predictive	D	Supports Sensitivity Response	2	accepted	EID7199 This preclinical study proposed to use a combination therapy of an MEK inhibitor (e.g. trametinib) and an mTOR inhibitor (e.g. everolimus) for the treatment of pediatric low-grade gliomas (PLGGs) with… (full text at CIViC) PMID 29156677 · Jain et al., 2017 · Open in CIViC	civic
Selumetinib	Childhood Pilocytic Astrocytoma	Predictive	D	Supports Sensitivity Response	2	accepted	EID8943 In this preclinical experiment, a pediatric pilocytic astrocytoma cell line (DKFZ-BT66) harboring KIAA1549:BRAF fusion was generated from a two year old patient. Treatment with selumetinib resulted in… (full text at CIViC) PMID 28002790 · Selt et al., 2017 · Open in CIViC	civic
Sorafenib + VemurafenibSubstitutes	Childhood Pilocytic Astrocytoma
BRAF V600E16
Vemurafenib	Childhood Pilocytic Astrocytoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID3777 In a case report, a 28 month old patient with a cervicomedullary low grade glioma compatible with pilocytic astrocytoma which was resected had a second lesion consistent with a ganglioglioma 3 years l… (full text at CIViC) PMID 25524464 · del Bufalo et al., 2014 · Open in CIViC	civic
Dabrafenib + TrametinibCombination	Cholangiocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID5902 Chemotherapy-refractory, metastatic cholangiocarcinoma with CNS involvement and a BRAF V600E mutation had a partial response at 8 weeks to dabrafenib and trametinib combination with complete radiologi… (full text at CIViC) PMID 28480077 · Kocsis et al., 2017 · Open in CIViC	civic
Irinotecan + Panitumumab + VemurafenibCombination	Cholangiocarcinoma
BRAF V6005
Vemurafenib	Cholangiocarcinoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID5905 Eight patients with BRAF V600 (7 with V600E, 1 with V600 unknown) mutated cholangiocarcinoma received vemurafenib. Only one patients showed partial response and duration of response of this patient wa… (full text at CIViC) PMID 26287849 · Hyman et al., 2015 · Open in CIViC	civic
Dabrafenib + TrametinibCombination	Cutaneous MelanomaALIAS	Predictive	A	Supports Sensitivity Response	5	accepted	EID1411 The Combi-v (NCT01597908) open-label, randomized phase 3 trial had 704 patients with metastatic melanoma with a BRAF V600 mutation. Patients were randomized to receive either a combination of dabrafen… (full text at CIViC) PMID 25399551 · Robert et al., 2015 · Open in CIViC	civic
Dabrafenib/Trametinib Regimen	Histiocytic Sarcoma
BRAF L597S2
MEK Inhibitor REC-4881	Cutaneous MelanomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID1460 Case report of a 69 year old patient with metastatic melanoma treated with MEK inhibitor TAK-733 in a clinical trial. A partial radiographic response with a decrease of 31% in the sum of maximum diame… (full text at CIViC) PMID 22798288 · Dahlman et al., 2012 · Open in CIViC	civic
Trametinib + VemurafenibSubstitutes	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID1459 Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutant–expressing cells led… (full text at CIViC) PMID 22798288 · Dahlman et al., 2012 · Open in CIViC	civic
BRAF D594G2
Sorafenib	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID6001 In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRN… (full text at CIViC) PMID 18794803 · Smalley et al., 2009 · Open in CIViC	civic
U0126	Cutaneous MelanomaALIAS	Predictive	D	Supports Resistance	3	accepted	EID6002 In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRN… (full text at CIViC) PMID 18794803 · Smalley et al., 2009 · Open in CIViC	civic
BRAF G469E2
Sorafenib	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID6003 In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRN… (full text at CIViC) PMID 18794803 · Smalley et al., 2009 · Open in CIViC	civic
U0126	Cutaneous MelanomaALIAS	Predictive	D	Supports Resistance	3	accepted	EID6004 In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition (U0126) but underwent apoptosis af… (full text at CIViC) PMID 18794803 · Smalley et al., 2009 · Open in CIViC	civic
BRAF D594A1
Mitogen-Activated Protein Kinase Kinase Inhibitor + SorafenibSubstitutes	Cutaneous MelanomaALIAS	Predictive	E	Supports Sensitivity Response	3	accepted	EID1454 Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF … (full text at CIViC) PMID 20141835 · Heidorn et al., 2010 · Open in CIViC	civic
BRAF K483M1
Mitogen-Activated Protein Kinase Kinase Inhibitor + SorafenibSubstitutes	Cutaneous MelanomaALIAS	Predictive	E	Supports Sensitivity Response	3	accepted	EID1457 Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF … (full text at CIViC) PMID 20141835 · Heidorn et al., 2010 · Open in CIViC	civic
BRAF D594V1
Sorafenib + TrametinibSubstitutes	Cutaneous MelanomaALIAS	Predictive	E	Supports Sensitivity Response	3	accepted	EID1456 Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF … (full text at CIViC) PMID 20141835 · Heidorn et al., 2010 · Open in CIViC	civic
BRAF L597V1
Trametinib	Cutaneous MelanomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID1463 Case report of a phase 1 study in advanced melanoma patients. 97 patients with melanoma were enrolled and treated with trametinib. One patient with a BRAF Leu597Val had a confirmed partial response wi… (full text at CIViC) PMID 22805292 · Falchook et al., 2012 · Open in CIViC	civic
BRAF Fusion1
Trametinib	Cutaneous MelanomaALIAS	Predictive	C	Supports Sensitivity Response	2	accepted	EID1570 Case report of a 47year old female patient with metastatic melanoma (BRAF, NRAS, KIT negative). A PPFIBP2-BRAF fusion was identified from DNA from a brain metastasis (inton 3 of PPFIBP2 fused to intro… (full text at CIViC) PMID 26072686 · Menzies et al., 2015 · Open in CIViC	civic
BRAF L597Q2
Trametinib	Cutaneous MelanomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID4905 Case study report including one patient with L597Q mutation-positive metastatic melanoma (M1b disease) treated with the MEK inhibitor trametinib. The L597Q patient achieved a RECIST partial response a… (full text at CIViC) PMID 24933606 · Bowyer et al., 2014 · Open in CIViC	civic
Trametinib + VemurafenibSubstitutes	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID1461 Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutant–expressing cells led… (full text at CIViC) PMID 22798288 · Dahlman et al., 2012 · Open in CIViC	civic
BRAF Fusion1
Trametinib	Cutaneous MelanomaALIAS	Predictive	C	Supports Sensitivity Response	2	accepted	EID13150 A 42 year old male patient with stage III cutaneous melanoma harboring an AGAP3::BRAF fusion was treated with the MEK inhibitor trametinib after prior pembrolizumab and experienced a response lasting … (full text at CIViC) PMID 35871080 · Moran et al., 2022 · Open in CIViC	civic
BRAF V600K1
Dabrafenib + TrametinibCombination	Cutaneous MelanomaALIAS	Predictive	B	Supports Sensitivity Response	3	accepted	EID4181 In a phase 3 clinical trial (NCT01597908) involving 704 patients with metastatic melanoma harboring BRAF V600 mutations, a subgroup analysis of patients with V600K mutations showed an objective respon… (full text at CIViC) PMID 25399551 · Robert et al., 2015 · Open in CIViC	civic
BRAF Fusion1
Vemurafenib	Cutaneous MelanomaALIAS	Predictive	D	Supports Resistance	3	accepted	EID1416 Foundation One NGS assay and targeted RNAseq identified PAPSS1-BRAF fusion in a melanoma sample. Further BRAF fusions (TRIM24-BRAF) were identified in TCGA and additional samples. Ectopic expression o… (full text at CIViC) PMID 24345920 · Hutchinson et al., 2013 · Open in CIViC	civic
BRAF L597R1
Trametinib + VemurafenibSubstitutes	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID1458 Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutant–expressing cells led… (full text at CIViC) PMID 22798288 · Dahlman et al., 2012 · Open in CIViC	civic
BRAF K601E1
Trametinib + VemurafenibSubstitutes	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID1462 Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutant–expressing cells led… (full text at CIViC) PMID 22798288 · Dahlman et al., 2012 · Open in CIViC	civic
BRAF T599dup1
Dabrafenib + TrametinibCombination	Ganglioglioma	Predictive	C	Supports Sensitivity Response	3	accepted	EID9789 A pediatric case of ganglioglioma was previously reported (PMID: 29434027) to harbor a BRAF p.T599dup variant (observed at VAF of 5.2%). The patient had a partial resection and was then treated with V… (full text at CIViC) PMID 33637608 · Miller et al., 2021 · Open in CIViC	civic
BRAF Exon 15 Mutation2
Regorafenib Anhydrous	Gastrointestinal Stromal Tumor	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID4121 This phase II clinical trial of regorafenib (NCT01068769) examined the long term safety and efficacy of regorafenib monotherapy in patients with metastatic and/or unresectable gastrointestinal stromal… (full text at CIViC) PMID 27371698 · Ben-Ami et al., 2016 · Open in CIViC	civic
〃	Gastrointestinal Stromal Tumor	Predictive	C	Supports Resistance	1	accepted	EID4605 This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients refractory to at least imatinib a… (full text at CIViC) PMID 22614970 · George et al., 2012 · Open in CIViC	civic
BRAF G596C1
Dabrafenib + TrametinibCombination	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	accepted	EID1738 Non-V600 BRAF mutations occur in about half of BRAF-mutated lung cancers, and their sensitivity to Dabrafenib and Trametinib is not well documented. In a cohort of 229 NSCLC patients that underwent mo… (full text at CIViC) PMID 28947956 · Noeparast et al., 2017 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (458)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

emaRegulatory8 approval records from 2 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Vemurafenib	EU EMA	Melanoma	Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma.	approved	Feb 17, 2012	ema
Vemurafenib	US FDA	—	Efficacy supplement 2017-11-06 (see label)	approved	Nov 6, 2017	openfda
Vemurafenib	US FDA	—	Efficacy supplement 2017-09-13 (see label)	approved	Sep 13, 2017	openfda
Vemurafenib	US FDA	—	Efficacy supplement 2016-08-31 (see label)

Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (629)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 333 recruiting · 118 active phase 3 · 2,987 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 151–200 of 629 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06958328	Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer(LAP100)	recruiting	Phase 3	356	NRG OncologyOTHER	2	Aug 25, 2026	clinicaltrials
NCT00463814	AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies	active not recruiting	Phase 1	58	AstraZenecaINDUSTRY	3	Aug 24, 2026	clinicaltrials
NCT02858921	Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma(Neo Trio)	active not recruiting	Phase 2	60	Melanoma Institute AustraliaOTHER	1	Aug 24, 2026	clinicaltrials
NCT03410875	A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia	active not recruiting	Phase 2	30	Memorial Sloan Kettering Cancer CenterOTHER	1	Aug 24, 2026	clinicaltrials
NCT04310020	Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients	active not recruiting	Phase 2	47	National Cancer Institute (NCI)NIH	1	Aug 24, 2026	clinicaltrials
NCT05775159	Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer	active not recruiting	Phase 2	294	AstraZenecaINDUSTRY	9	Aug 24, 2026	clinicaltrials
NCT06084481	Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400	recruiting	Phase 1	325	AbbVieINDUSTRY	8	Aug 24, 2026	clinicaltrials
NCT06586515	MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors(MOONRAY-01)	recruiting	Phase 1	630	Eli Lilly and CompanyINDUSTRY	9	Aug 24, 2026	clinicaltrials
NCT06803680	A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors	recruiting	Phase 1	90	BeOne MedicinesINDUSTRY	3	Aug 24, 2026	clinicaltrials
NCT04535401	Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines	active not recruiting	Phase 1	10	National Cancer Institute (NCI)NIH	1	Aug 21, 2026	clinicaltrials
NCT05554367	Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial	active not recruiting	Phase 2	199	National Cancer Institute (NCI)NIH	2	Aug 21, 2026	clinicaltrials
NCT05797168	Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors(FONTANA)	recruiting	Phase 1 / Phase 2	602	AstraZenecaINDUSTRY	12	Aug 21, 2026	clinicaltrials
NCT07209111	A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)(KANDLELIT-014)	recruiting	Phase 2	150	Merck Sharp & Dohme LLCINDUSTRY	19	Aug 21, 2026	clinicaltrials
NCT07779538	Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer	not yet recruiting	Phase 3	420	Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY	1	Aug 21, 2026	clinicaltrials
NCT04008030	A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)(CheckMate 8HW)	active not recruiting	Phase 3	839	Bristol-Myers SquibbINDUSTRY	24	Aug 20, 2026	clinicaltrials
NCT05636111	Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer	recruiting	Phase 1	34	M.D. Anderson Cancer CenterOTHER	1	Aug 20, 2026	clinicaltrials
NCT06741644	A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors	recruiting	Phase 1 / Phase 2	800	CStone PharmaceuticalsINDUSTRY	3	Aug 20, 2026	clinicaltrials
NCT07619313	AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer	recruiting	Phase 1	46	Jonsson Comprehensive Cancer CenterOTHER	1	Aug 20, 2026	clinicaltrials
NCT07770100	Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)	not yet recruiting	Phase 2	35	Mark BernardOTHER	1	Aug 20, 2026	clinicaltrials
NCT07776171	Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer	not yet recruiting	Phase 2	176	Sun Yat-sen UniversityOTHER	1	Aug 20, 2026	clinicaltrials
NCT05317858	Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets(LIMITLESS)	recruiting	Phase 3	30	InSightecINDUSTRY	3	Aug 19, 2026	clinicaltrials
NCT07214298	Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma	recruiting	Phase 1 / Phase 2	35	Roswell Park Cancer InstituteOTHER	1	Aug 19, 2026	clinicaltrials
NCT07774611	An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors	not yet recruiting	Phase 1 / Phase 2	180	Hangzhou Sumgen Biotech Co., Ltd.INDUSTRY	1	Aug 19, 2026	clinicaltrials
NCT04485559	Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)	recruiting	Phase 1	50	University of California, San FranciscoOTHER	1	Aug 18, 2026	clinicaltrials
NCT04598009	Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma	recruiting	Phase 2	25	University of California, San FranciscoOTHER	1	Aug 18, 2026	clinicaltrials
NCT06792695	A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer(CANTOR)	recruiting	Phase 2	80	AstraZenecaINDUSTRY	12	Aug 18, 2026	clinicaltrials
NCT07620574	Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study	enrolling by invitation	Phase 3	5,000	ExelixisINDUSTRY	1	Aug 18, 2026	clinicaltrials
NCT02955940	An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib	active not recruiting	Phase 2	10	Incyte CorporationINDUSTRY	2	Aug 17, 2026	clinicaltrials
NCT04891289	Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery	recruiting	Phase 2	164	Memorial Sloan Kettering Cancer CenterOTHER	2	Aug 17, 2026	clinicaltrials
NCT05919264	FOG-001 in Locally Advanced or Metastatic Solid Tumors	recruiting	Phase 1 / Phase 2	619	Parabilis Medicines, Inc.INDUSTRY	2	Aug 17, 2026	clinicaltrials
NCT07440290	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE)	recruiting	Phase 2 / Phase 3	30	Cancer Research UKOTHER	1	Aug 17, 2026	clinicaltrials
NCT05231122	Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer	recruiting	Phase 2	80	Roswell Park Cancer InstituteOTHER	1	Aug 14, 2026	clinicaltrials
NCT05722327	Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer	active not recruiting	Phase 1	24	M.D. Anderson Cancer CenterOTHER	1	Aug 14, 2026	clinicaltrials
NCT07262567	Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer	recruiting	Phase 3	320	Genfleet Therapeutics (Shanghai) Inc.INDUSTRY	1	Aug 14, 2026	clinicaltrials
NCT02971501	Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases	active not recruiting	Phase 2	5	National Cancer Institute (NCI)NIH	1	Aug 13, 2026	clinicaltrials
NCT03871257	A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma	active not recruiting	Phase 3	165	National Cancer Institute (NCI)NIH	3	Aug 13, 2026	clinicaltrials
NCT07042802	A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer	recruiting	Phase 1 / Phase 2	180	Nanjing Leads Biolabs Co.,LtdINDUSTRY	1	Aug 13, 2026	clinicaltrials
NCT03943173	Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery	active not recruiting	Early Phase 1	15	M.D. Anderson Cancer CenterOTHER	1	Aug 12, 2026	clinicaltrials
NCT06797336	A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors	recruiting	Phase 1	240	PAQ Therapeutics, Inc.INDUSTRY	2	Aug 12, 2026	clinicaltrials
NCT01989585	Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma	active not recruiting	Phase 1 / Phase 2	75	National Cancer Institute (NCI)NIH	1	Aug 11, 2026	clinicaltrials
NCT02320435	A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial	active not recruiting	Phase 3	154	Hoffmann-La RocheINDUSTRY	15	Aug 11, 2026	clinicaltrials
NCT02884648	Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery	active not recruiting	Phase 2	35	M.D. Anderson Cancer CenterOTHER	1	Aug 11, 2026	clinicaltrials
NCT03392246	A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer	active not recruiting	Phase 2	25	Dana-Farber Cancer InstituteOTHER	1	Aug 11, 2026	clinicaltrials
NCT03708224	Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck	active not recruiting	Phase 2	55	Alain AlgaziOTHER	1	Aug 11, 2026	clinicaltrials
NCT04526782	ENCOrafenib With Binimetinib in bRAF NSCLC(ENCO-BRAF)	active not recruiting	Phase 2	119	Intergroupe Francophone de Cancerologie ThoraciqueOTHER	1	Aug 11, 2026	clinicaltrials
NCT04675710	Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer	active not recruiting	Phase 2	30	M.D. Anderson Cancer CenterOTHER	1	Aug 11, 2026	clinicaltrials
NCT04837716	Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer	active not recruiting	Phase 1	12	M.D. Anderson Cancer CenterOTHER	1	Aug 11, 2026	clinicaltrials
NCT06666348	Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK(MIRV)	recruiting	Phase 1 / Phase 2	50	St. Justine's HospitalOTHER	1	Aug 11, 2026	clinicaltrials
NCT07071714	A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer	active not recruiting	Phase 2	103	Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY	1	Aug 11, 2026	clinicaltrials
NCT02231775	Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation	active not recruiting	Phase 2	58	M.D. Anderson Cancer CenterOTHER	1	Aug 10, 2026	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (4)

Associated cancers (32)

Drugs with predictive evidence (43)

Predictive evidence items (214)

Approvals mentioning the linked drugs (458)

Active trials (629)

Linked publications (142)